AL002 is an investigational, humanized, TREM2-selective agonistic monoclonal antibody in Phase 2 trials for the treatment of early Alzheimer’s disease (Jackson et al. 2022). The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.